IDT Biologika

What IDT Biologika does

IDT Biologika is a Germany-based Contract Development and Manufacturing Organization (CDMO) specializing in viral vaccines, cell and gene therapies, and sterile injectable biologics. Founded in 1921 in Dessau-Rosslau, the company operates from a global headquarters and primary manufacturing/R&D campus in Saxony-Anhalt, Germany, with additional GMP manufacturing capacity in Magdeburg and a US subsidiary in Rockville, Maryland. Its technical platform spans microbial and mammalian cell culture drug substance manufacturing, aseptic fill-finish (liquid and lyophilized), BSL-2 viral vector production, and proprietary EBx®/EB66® avian cell line technology. The company holds EMA, FDA, and ANVISA approvals and was the first German firm to have its pandemic readiness confirmed by the German government.

IDT Biologika generates revenue through fee-for-service contract development, GMP drug substance manufacturing, aseptic fill-finish, and quality control/release services billed to pharmaceutical, biotech, and vaccine developer clients under multi-year clinical and commercial supply agreements. Pricing is project-based and confidential, with revenue tied to program milestones, batch campaigns, and recurring commercial supply contracts. Customer segments span large pharma and biotech companies developing vaccines and biologics, viral vector and gene therapy developers requiring BSL-2 capacity, and government/public health agencies such as CEPI funding outbreak preparedness programs. Named commercial relationships include MSD (Ervebo Ebola vaccine manufacturing), CEPI, Hilleman Laboratories, and Vaxxas (needle-free vaccine patch collaboration).

Since October 2024, IDT Biologika has operated as a 60%-owned subsidiary of South Korea's SK bioscience, functioning as the European manufacturing hub within SK bioscience's global vaccine network. The company employs approximately 1,600 people across its global operations and has invested approximately €600 million cumulatively in facility expansion, fill-finish capacity, and BSL-2 infrastructure, including a newly completed multifunctional vaccine production building and a high-speed aseptic isolator filling line capable of up to 32,000 vials per hour. GTM motion is direct enterprise field sales supplemented by active participation in industry conferences (DCAT Week, BPI Europe, BIO) and strategic co-development alliances that expand geographic reach.

Name

IDT Biologika

Legal name

IDT Biologika GmbH

Website

https://idt-biologika.com

Company type

Private

Founded year

1921

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

IDT Biologika is a Germany-headquartered CDMO providing end-to-end contract development, GMP manufacturing, and aseptic fill-finish for viral vaccines, cell and gene therapies, and sterile injectables to pharma, biotech, and government clients.

Ownership category

akta.pro rank

Product category

Biologics Contract Development and Manufacturing (CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

akta.pro secondary industries

Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Biologics contract manufacturing
• Vaccine CDMO services
• Viral vector production
• Aseptic fill-finish
• Cell line development

Headquarters

HQ city

Dessau

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Biologics CDMO services (contract development & manufacturing): Fee-for-service contract development, GMP drug substance manufacturing, aseptic fill-finish, and QC/release services billed to pharma, biotech, and vaccine developer clients under multi-year clinical and commercial supply agreements. Revenue is tied to program milestones, batch campaigns, and ongoing commercial supply contracts.
2. Vaccine CDMO and commercial supply contracts: Long-term commercial supply contracts for vaccines (including Ebola and other infectious disease programs), generating recurring manufacturing revenue as approved products are released to market.
3. Viral vector and gene therapy manufacturing services: BSL-2 viral vector and gene therapy CDMO services for vaccine and gene therapy developers, billed on a project / campaign basis under development and commercial supply contracts.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

IDT Biologika is a biologics Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for the development, GMP manufacturing, aseptic fill-finish, and commercial supply of viral vaccines, cell and gene therapy vectors, and sterile injectable biologics. Services span proprietary cell line development through drug substance manufacturing (microbial and mammalian cell culture), BSL-2 viral vector production, aseptic fill-finish including lyophilization, QC/analytics, and regulatory support, delivered from German and US sites to pharmaceutical, biotech, and public-health clients globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Vaccines CDMO Services End-to-end contract development, GMP manufacturing, and commercial supply services for viral vaccines, leveraging over 100 years of vaccine manufacturing expertise and state-of-the-art BSL-2 facilities, offered to pharmaceutical, biotech, and public-health clients globally.
• Cell & Gene Therapy CDMO Services Contract development and GMP manufacturing services for viral vectors and gene therapy products, including high-containment BSL-2 production, analytics, and release, targeted at cell and gene therapy developers needing scarce viral vector capacity.
• Sterile Injectables CDMO Services Customized end-to-end CDMO solutions for aseptic fill-finish and lyophilization of sterile injectable biologics, supporting clinical and commercial supply for pharma and biotech clients.
• Cell Line Development Services Proprietary cell line development using the EBx® and EB66® avian cell line platforms, providing a scalable alternative to traditional egg- and mammalian-cell systems for vaccine and complex biologics production at industrial scale.
• Process Development Services GMP process development services covering upstream, downstream, and scale-up activities to support client biologics and vaccine programs from cell line to commercial scale.
• Analytical Development Services Analytical method development and validation services to support characterization, release, and stability testing of biologics, vaccines, and viral vectors under GMP.
• Drug Substance Manufacturing (Microbial and Mammalian Cell Culture) GMP drug substance manufacturing using microbial (bacterial) fermentation and mammalian cell culture platforms (200L to 2,000L scale) for recombinant proteins, monoclonal antibodies, plasmid DNA, and viral vectors, supporting both clinical and commercial supply.
• Aseptic Fill-Finish & Lyophilization Services Aseptic fill-finish of liquid and lyophilized (freeze-dried) parenteral biologics including high-speed vial filling with 100% in-process control, supporting clinical and commercial supply.
• Secondary Packaging Services Secondary packaging of vials and biologics products as part of the company's end-to-end CDMO offering for commercial supply.
• Quality Control & Analytics Services GMP quality control and release analytics, including in-process and release testing, stability, and method validation for biologics, vaccines, and viral vectors.
• Regulatory Support Services Regulatory support services for biologics, vaccines, and viral vector programs, leveraging established EMA, FDA and ANVISA approvals and CEPI/WHO program experience.

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature7 records

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

• SK bioscienceflagshipStrategic or Co-development Partner · 1 January 2024SK bioscience acquired a controlling stake in IDT Biologika in 2024, becoming the parent company and strategic anchor shareholder. The partnership combines SK bioscience's global vaccine pipeline and commercial reach with IDT's CDMO capabilities to accelerate vaccine development and pandemic preparedness, including a joint focus on EU-based vaccine manufacturing.
• MSD (Merck)coreStrategic or Co-development Partner · 1 January 2024IDT Biologika is a manufacturing partner for MSD's (Merck & Co.) Ervebo Ebola vaccine, producing the vaccine at its BSL-2 facilities as part of the global supply chain.
• VaxxasminorStrategic or Co-development Partner · 1 January 2024IDT Biologika is collaborating with Vaxxas on an EU-funded vaccine project (announced via SK bioscience / IDT channel) to support needle-free vaccine patch technology and development, with SK bioscience providing vaccine antigen and IDT contributing development and manufacturing capabilities.
• Hilleman LaboratoriesminorStrategic or Co-development Partner · 1 January 2024Hilleman Laboratories is co-developing an Ebola vaccine candidate with IDT Biologika, combining Hilleman's research with IDT's GMP manufacturing capabilities to advance a low-cost, globally accessible Ebola vaccine.
• Klocke GroupminorStrategic or Co-development Partner · 1 January 2022Klocke Group was the previous owner of IDT Biologika prior to the SK bioscience acquisition; the divestiture/realignment separated IDT's human health CDMO business from the Klocke-owned animal health packaging operations.

Scale indicators6 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Lonza Group: The largest global biologics CDMO offering mammalian and microbial drug substance, viral vector, and aseptic fill-finish services to pharma and biotech — directly comparable to IDT's full-stack CDMO offering across vaccines, gene therapy, and sterile injectables.
• Recipharm: European-headquartered CDMO with biologics, sterile fill-finish, and vaccine capabilities — comparable geographic positioning and CDMO service mix to IDT Biologika.
• Fujifilm Diosynth Biotechnologies: Major CDMO providing vaccine, gene therapy, and recombinant protein manufacturing with BSL-2 capacity — direct competitor in viral vaccine and viral vector CDMO services.
• Samsung Biologics: Asian-headquartered biologics CDMO with large-scale drug substance and fill-finish capacity serving global pharma — same business model as IDT Biologika and increasingly competitive in vaccine and gene therapy manufacturing.
• Catalent (Novo Holdings): Global CDMO with significant biologics, viral vector, and sterile injectable fill-finish capacity, serving vaccine and gene therapy developers — direct competitor for IDT's core service lines.
• AGC Biologics: Global CDMO offering mammalian and microbial biologics, cell and gene therapy, and fill-finish services — directly comparable mid-sized competitor with overlapping modalities and customer segments.
• WuXi Biologics: One of the largest global biologics CDMOs with end-to-end capabilities from cell line development to commercial manufacturing — directly comparable service portfolio and target customer base to IDT Biologika.

Broad incumbents

• Thermo Fisher Scientific (Patheon CDMO): Diversified life sciences giant whose Patheon CDMO division offers biologics drug substance, viral vector services, and sterile fill-finish — broader incumbent competitor across multiple CDMO service lines.

Emerging players

• Vibalogics (recipharm/CureX): Specialized CDMO focused on BSL-2 viral vector and live virus vaccine manufacturing — narrow but directly overlapping niche with IDT's viral vector and vaccine services.

Regional players

• Rentschler Biologics: German-based, family-owned biologics CDMO specializing in mammalian cell culture drug substance — close European regional peer to IDT with overlapping pharma/biotech customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/idtbiologika
• Facebookfacebook.com/idtbiologika
• LinkedInlinkedin.com/company/idtbiologika

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDT Biologika